Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
C$10.60
-3.8%
C$10.60
C$3.50
C$15.75
C$168.68MN/A12,671 shs3,402 shs
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
$10.30
$9.72
$18.20
$450MN/A2.07 million shs40,482 shs
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$10.70
$10.70
$3.95
$11.35
$292.42M2.38327,575 shs54 shs
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$1.34
+25.9%
$0.67
$0.27
$1.31
$48.51M0.442.53 million shs2.71 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.00%0.00%0.00%0.00%0.00%
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
0.00%0.00%0.00%0.00%0.00%
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.00%0.00%0.00%0.00%0.00%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
+25.94%+20.27%+136.91%+270.94%+33.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/AN/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
1.7811 of 5 stars
3.53.00.00.00.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.00
N/AC$15.0041.51% Upside
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
0.00
N/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.00
N/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
3.00
Buy$4.00199.63% Upside

Current Analyst Ratings Breakdown

Latest HBP, BCT, FRX, and IPA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AC$3.34 per share3.17C$3.60 per shareN/A
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/A$0.56 per shareN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$937.80M0.31$1.97 per share5.43$3.40 per share3.15
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$18.16M3.36N/AN/A$0.93 per share1.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/A-C$0.38N/AN/AN/AN/AN/AN/A
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
-$7.92MN/A0.00N/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$48.50M$1.776.05N/A5.17%66.00%15.67%N/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$20.13M-$1.16N/AN/AN/A-190.76%-88.87%-49.26%8/4/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AN/AN/AN/A
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.05
129.63
128.68
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A
0.37
0.37
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.75
2.05
0.95
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.45
2.32
2.11
CompanyEmployeesShares OutstandingFree FloatOptionable
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
515.91 millionN/ANot Optionable
Forest Road Acquisition Corp. stock logo
FRX
Forest Road Acquisition
N/A37.50 millionN/ANot Optionable
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
1,10027.33 million24.34 millionOptionable
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
8045.76 million42.64 millionNot Optionable

Recent News About These Companies

ImmunoPrecise Antibodies reports Q3 EPS (C$0.66) vs. (C$0.10) last year

New MarketBeat Followers Over Time

Media Sentiment Over Time

BriaCell Therapeutics stock logo

BriaCell Therapeutics CVE:BCT

C$10.60 -0.42 (-3.81%)
As of 12/30/2021

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Forest Road Acquisition stock logo

Forest Road Acquisition NYSE:FRX

Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.

Huttig Building Products stock logo

Huttig Building Products NASDAQ:HBP

Huttig Building Products, Inc., together with its subsidiaries, distributes millwork, building materials, and wood products for new residential construction, in-home improvement, remodeling, and repair works in the United States. The company offers various millwork products, including exterior and interior doors, pre-hung and factory finished door units, windows, patio doors, mouldings, frames, stair parts, and columns under the Therma-Tru, Masonite, Woodgrain, HB&G, Simpson Door, Final Frame, BrasPine, Arauco, Windsor Windows, and Rogue Valley Door brands. It also provides general building products, such as fasteners and connectors, roofing, siding, insulation, flashing, housewrap, decking, railings, and other miscellaneous building products under the Huttig-Grip, Louisiana-Pacific, Simpson Strong-Tie, TimberTech, AZEK, RDI, GAF Roofing, Maibec, Knauf, GCP Technologies, Fiberon, Alpha Protech, MFM, Lomanco, and Fortifiber brands. In addition, the company offers wood products comprising engineered wood products used in floor systems, wood panels, and lumber; and value-added services, such as floor system take-offs, cut-to-length packages and just-in-time, and cross-dock delivery under the Louisiana-Pacific and Rosboro brands. It markets and sells its products through a network of 25 wholesale distribution centers serving approximately 41 states to building materials dealers, national buying groups, home centers, and industrial users comprising makers of manufactured homes. Huttig Building Products, Inc. was founded in 1865 and is headquartered in St. Louis, Missouri.

ImmunoPrecise Antibodies stock logo

ImmunoPrecise Antibodies NASDAQ:IPA

$1.34 +0.28 (+25.94%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$1.34 0.00 (0.00%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.